Palonosetron hydrochlorideCAS# 135729-62-3 |
- GDC-0068 (RG7440)
Catalog No.:BCC1271
CAS No.:1001264-89-6
- MK-2206 dihydrochloride
Catalog No.:BCC1274
CAS No.:1032350-13-2
- AZD5363
Catalog No.:BCC1073
CAS No.:1143532-39-1
- A-443654
Catalog No.:BCC1321
CAS No.:552325-16-3
- AKT inhibitor VIII
Catalog No.:BCC1334
CAS No.:612847-09-3
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 135729-62-3 | SDF | Download SDF |
| PubChem ID | 6918303 | Appearance | Powder |
| Formula | C19H25ClN2O | M.Wt | 332.87 |
| Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
| Solubility | H2O : 100 mg/mL (300.42 mM; Need ultrasonic) DMSO : 3.33 mg/mL (10.00 mM; Need ultrasonic) | ||
| Chemical Name | (3aS)-2-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-3a,4,5,6-tetrahydro-3H-benzo[de]isoquinolin-1-one;hydrochloride | ||
| SMILES | C1CC2CN(C(=O)C3=C2C(=CC=C3)C1)C4CN5CCC4CC5.Cl | ||
| Standard InChIKey | OLDRWYVIKMSFFB-SSPJITILSA-N | ||
| Standard InChI | InChI=1S/C19H24N2O.ClH/c22-19-16-6-2-4-14-3-1-5-15(18(14)16)11-21(19)17-12-20-9-7-13(17)8-10-20;/h2,4,6,13,15,17H,1,3,5,7-12H2;1H/t15-,17-;/m1./s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Palonosetron hydrochloride is the only serotonin receptor antagonist approved for prevention of delayed chemotherapy-induced nausea and vomiting (CINV) caused by moderate emetogenic chemotherapy (MEC). |
| Targets | 5-HT Receptor |
| In vitro | An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting.[Pubmed: 23414148]Expert Opin Pharmacother. 2013 Apr;14(5):629-41. Nausea and vomiting are well recognized in different clinical situations, suggesting that no single mechanism is likely to be responsible for their production. |
| In vivo | The effect of palonosetron hydrochloride in the prevention of chemotherapy-induced moderate and severe nausea and vomiting.[Pubmed: 23737892]Exp Ther Med. 2013 May;5(5):1418-1426.The current study aimed to evaluate the efficacy and safety of Palonosetron hydrochloride injection for preventing chemotherapy-induced moderate and severe nausea and vomiting. |
| Structure Identification | J Chromatogr A. 2014 May 16;1342:86-91.Effect of low concentration sodium dodecyl sulfate on the electromigration of palonosetron hydrochloride stereoisomers in micellar electrokinetic chromatography.[Pubmed: 24709591]
|
Palonosetron hydrochloride Dilution Calculator
Palonosetron hydrochloride Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.0042 mL | 15.0209 mL | 30.0418 mL | 60.0835 mL | 75.1044 mL |
| 5 mM | 0.6008 mL | 3.0042 mL | 6.0084 mL | 12.0167 mL | 15.0209 mL |
| 10 mM | 0.3004 mL | 1.5021 mL | 3.0042 mL | 6.0084 mL | 7.5104 mL |
| 50 mM | 0.0601 mL | 0.3004 mL | 0.6008 mL | 1.2017 mL | 1.5021 mL |
| 100 mM | 0.03 mL | 0.1502 mL | 0.3004 mL | 0.6008 mL | 0.751 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Palonosetron Hcl is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV).
- Palonosetron
Catalog No.:BCC1834
CAS No.:135729-61-2
- MDL 29,913
Catalog No.:BCC5729
CAS No.:135721-56-1
- ML 228
Catalog No.:BCC2435
CAS No.:1357171-62-0
- c-Met inhibitor 1
Catalog No.:BCC1488
CAS No.:1357072-61-7
- N-Acetylglycyl-D-glutamic acid
Catalog No.:BCC6634
CAS No.:135701-69-8
- HG-14-10-04
Catalog No.:BCC5392
CAS No.:1356962-34-9
- AZD-3463
Catalog No.:BCC3907
CAS No.:1356962-20-3
- ent-3-Oxokaurane-16,17-diol
Catalog No.:BCN6188
CAS No.:135683-73-7
- Narchinol B
Catalog No.:BCN7796
CAS No.:1356822-09-7
- Fmoc-Cha-OH
Catalog No.:BCC3160
CAS No.:135673-97-1
- 17-Methylparsonsianidine
Catalog No.:BCN2093
CAS No.:135637-68-2
- CP 80633
Catalog No.:BCC7463
CAS No.:135637-46-6
- Taxinine M
Catalog No.:BCN6942
CAS No.:135730-55-1
- OG-L002
Catalog No.:BCC4549
CAS No.:1357302-64-7
- Nonin A
Catalog No.:BCN7149
CAS No.:1357351-29-1
- RGFP966
Catalog No.:BCC3991
CAS No.:1357389-11-7
- Boc-Glu(OBzl)-OH
Catalog No.:BCC3389
CAS No.:13574-13-5
- Isoforsythiaside
Catalog No.:BCN5413
CAS No.:1357910-26-9
- Koumine
Catalog No.:BCN6190
CAS No.:1358-76-5
- erythro-Guaiacylglycerol beta-dihydroconiferyl ether
Catalog No.:BCN7025
CAS No.:135820-77-8
- Blumenol C glucoside
Catalog No.:BCN6189
CAS No.:135820-80-3
- H-D-Asp(OtBu)-OtBu.HCl
Catalog No.:BCC2898
CAS No.:135904-71-1
- Lupinol C
Catalog No.:BCN4809
CAS No.:135905-53-2
- RP 67580
Catalog No.:BCC7134
CAS No.:135911-02-3
An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting.[Pubmed:23414148]
Expert Opin Pharmacother. 2013 Apr;14(5):629-41.
INTRODUCTION: Nausea and vomiting are well recognized in different clinical situations, suggesting that no single mechanism is likely to be responsible for their production. Chemotherapy-induced nausea and vomiting (CINV) can have a negative impact on quality of life and this may lead to a refusal of curative therapy or to a decline in palliative benefits offered by cytotoxic treatment. Palonosetron is a new agent in the class of 5-HT3 receptor antagonists (5-HT3RAs), and differs from the other agents by its higher receptor-binding affinity and longer half-life. These pharmacological properties have resulted in improved antiemetic activity in clinical trials, particularly in the treatment of delayed CINV following moderate emetogenic chemotherapy (MEC). AREA COVERED: A systematic review of the medical literature was completed to inform this update. MEDLINE, the Cochrane Collaboration Library and meeting materials from ASCO and MASCC were all searched. EXPERT OPINION: Palonosetron was the only serotonin receptor antagonist approved for prevention of delayed CINV caused by MEC and its use was incorporated in guideline recommendations. To date, several treatment settings such as multiple day chemotherapy require further studies to improve emesis related to therapy.
The effect of palonosetron hydrochloride in the prevention of chemotherapy-induced moderate and severe nausea and vomiting.[Pubmed:23737892]
Exp Ther Med. 2013 May;5(5):1418-1426.
The current study aimed to evaluate the efficacy and safety of Palonosetron hydrochloride injection for preventing chemotherapy-induced moderate and severe nausea and vomiting. A multi-centered, randomly stratified, double-blind, double-dummy, parallel-group and positive-controlled trial was performed. A total of 240 patients who underwent chemotherapy treatment which induced moderate or severe vomiting were divided into the experimental and control groups. Half an hour before chemotherapy, the experimental group received a 0.25-mg Palonosetron hydrochloride injection, whereas the control group received a 3-mg granisetron injection. The acute vomiting complete remission rate (CRR) of the experimental group was not significantly different compared with that of the control group (P=0.35). The delayed vomiting CRR of the experimental group was significantly higher compared with that of the control group (P=0.002). No difference in full course vomiting CRR, vomiting control time, treatment failure time or acute nausea CRR was identified between the two groups. No significant differences in adverse events were observed between the experimental group and the control group. No significant differences in adverse reactions occurred between the experimental group and the control group (12.50%). Palonosetron hydrochloride injection had a better effect on delayed vomiting CRR than granisetron hydrochloride injection. The two injections exhibited similar effects on acute vomiting CRR, full course vomiting CRR, vomiting control time, treatment failure time (days), acute nausea CRR and adverse events.
Effect of low concentration sodium dodecyl sulfate on the electromigration of palonosetron hydrochloride stereoisomers in micellar electrokinetic chromatography.[Pubmed:24709591]
J Chromatogr A. 2014 May 16;1342:86-91.
The effect of low concentrations of sodium dodecyl sulfate (SDS) on the separation of Palonosetron hydrochloride (PALO) stereoisomers by micellar electrokinetic chromatography (MEKC) has been investigated. It was found that the addition of SDS prolongs the migration time and the migration order of four stereoisomers changes regularly with the SDS concentration. Good separations for all the four stereoisomers were achieved at appropriate SDS concentration. The effect of SDS on the electromigration (mobilities) of PALO stereoisomers has been studied, in order to explain its effect on the separation by MEKC. It was found that low concentrations of SDS added into the separation media forms negatively charged complexes with PALO stereoisomers and hence reverses their electromigration direction. Furthermore, the migration order between two enantiomeric pairs is also reversed because the enantiomeric pair with a bigger positive mobility than that of another pair turns to have a bigger negative mobility when bound with SDS. Based on these results, the effect of SDS on the MEKC separation of PALO stereoisomers was elucidated reasonably. The performance of the developed chiral MEKC method was validated by the analysis of a real sample.
